Short CV

Prof. Dr. Katharina Schindowski Zimmermann worked more than 6 years in R&D in Pharma industry (Sanofi, Boehringer Ingelheim) and clinical research (Quintiles) and has successfully developed several AD in vivo models and in vitro assays for compound HTS screening, PK-PD studies, proof-of-concept and mechanism-of action, CNS drug delivery and basic research. She has more than 18 years experience in CNS research and development of therapeutic antibodies with a strong focus on AD. In 2010 she was appointed as full professor for Molecular Pharmacology at Biberach University of Applied Science.


Current research

The World Health Organisation (WHO) estimates that more than a billion people worldwide are suffering from diseases of the CNS. AD is the most common neurodegenerative dementia in the industrialised world, with prevalence rates well over 30% in the over 80-years-old population. AD causes enormous costs to the social healthcare systems, as well as personal tragedies for the patients, families and caregivers. Like most neuro-degenerative diseases AD has a poor prognosis and only symptomatic therapy is currently available. Efficient treatment strategies are still limited and an ageing society in demographic change presents an enormous chal-lenge to the health systems of industrialised nations. A highly critical point in that context is the low central availability of drugs due to the blood brain barrier (BBB) and nearly all of the larger molecules such as peptides and proteins fail to cross the BBB. The current state-of-the-art to deliver drugs with a low central bioavailability is intrathecal, intracerebroventricular or intraparenchymal injections. They are used to deliver drugs directly to the CSF of the CNS, some of them being given chronically via an implanted intrathecal micropump. Although, such delivery systems are well established, these routes of administration are invasive, require a surgery with high risks, have a lower patient compliance and can be poorly controlled.
Intranasal nose to brain (N2B) delivery to the upper third of the nasal cavity bypasses the BBB to rapidly target therapeutics to the CNS along the olfactory and trigeminal neural pathways.
Further reading link:


CNS Drug Delivery & Antibody Engineering

  • intranasal CNS delivery
  • in vitro and ex vitro models
  • refined in vitro rodent model
  • interaction etween biopharmaceutic and mucosal imune system
  • protein formulation for intranasal delivery
  • engineering of domain antibodies
  • assay and model development


Alle einblenden

PhD students

Master, Bachelor and internship students (present and alumni)


Please see

for latest dissemination.

Research projects

Alle einblenden


FcRn in N2B


Intranasal drug delivery with domain antibodies

3D for 3R

Intranasal delivery of proteins